|
NOT FOR RELEASE, PUBLICATION OR
DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE
REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH
RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS FOR
INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY
JURISDICTION.
THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION.
|
|
|
21 June
2024
|
ANGLE plc (the
"Company")
Results of Open
Offer
ANGLE plc (AIM:AGL), a world-leading
liquid biopsy company with innovative circulating tumour cell (CTC)
solutions for use in research, drug development and clinical
oncology, is pleased to announce that, pursuant to the Open Offer
announced on 5 June 2024, it has received valid applications for a
total of 3,561,121 Open Offer Shares from Qualifying
Shareholders.
The Open Offer raised gross proceeds
of £0.5m at the Issue Price, which will be used to strengthen the
Company's balance sheet. In aggregate, £9.3m of gross proceeds have been
raised pursuant to the Placing, Subscription and Open
Offer.
The Open Offer Shares, when issued,
will be fully paid and rank pari passu in all respects with the
existing ordinary shares of the Company. Application has been
made for the Open Offer Shares to be admitted to trading on AIM.
Admission and settlement of the Open Offer Shares is expected
to take place at 8.00 a.m. on 24 June 2024.
Total voting rights
Following Second Admission, the
Company will have a total of 322,641,668 ordinary shares in issue.
With effect from Second Admission, this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company, under the Disclosure
Guidance and Transparency Rules of the Financial Conduct
Authority.
Unless otherwise stated, capitalised terms not otherwise
defined in the text of this announcement have the same meanings
ascribed to them as in the Launch Announcement published by the
Company on 5 June 2024.
For
further information:
|
ANGLE plc
|
+44
(0) 1483 343434
|
|
Andrew Newland, Chief
Executive
Ian Griffiths, Finance
Director
|
|
|
Berenberg (NOMAD & Corporate Broker)
Toby Flaux, Ciaran Walsh, Milo
Bonser, Brooke Harris-Lowing
|
+44
(0) 20 3207 7800
|
|
FTI
Consulting (Financial PR)
Simon Conway, Ciara
Martin
Matthew Ventimiglia (US)
|
+44
(0) 203 727 1000
+1
(212) 850 5624
|
About ANGLE plc
ANGLE is a world-leading liquid
biopsy company with innovative circulating tumour cell (CTC)
solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting
technology known as the Parsortix® PC1 System enables complete
downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular
analysis.
ANGLE's commercial businesses are
focusing on diagnostic products and clinical services. Diagnostic
products include the Parsortix® system, associated consumables and
assays. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made
assay development and clinical trial testing for pharma.
Over 90 peer-reviewed publications
have demonstrated the performance of the Parsortix system. For more
information, visit https://angleplc.com/.